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ORIGINAL ARTICLE
Background/Aims: We examined the effects of cilostazol on mitogen-activated protein kinase (MAPK) activity
and its relationship with cilostazol-mediated protection against apoptosis in lipopolysaccharide (LPS)-treated
endothelial cells.
Methods: Human umbilical vein endothelial cells (HUVECs) were exposed to LPS and cilostazol with and without
specific inhibitors of MAPKs; changes in MAPK activity in association with cell viability and apoptotic signaling
were investigated.
Results: Cilostazol protected HUVECs against LPS-induced apoptosis by suppressing the mitochondrial
permeability transition, cytosolic release of cytochrome c, and subsequent activation of caspases, stimulating
extracellullar signal-regulated kinase (ERK1/2) and p38 MAPK signaling, and increasing phosphorylated cAMP-
responsive element-binding protein (CREB) and Bcl-2 expression, while suppressing Bax expression. These
cilostazol-mediated cellular events were effectively blocked by MAPK/ERK kinase (MEK1/2) and p38 MAPK
inhibitors.
Conclusions: Cilostazol protects HUVECs against LPS-induced apoptosis by suppressing mitochondria-
dependent apoptotic signaling. Activation of ERK1/2 and p38 MAPKs, and subsequent stimulation of CREB
phosphorylation and Bcl-2 expression, may be responsible for the cellular signaling mechanism of cilostazol-
mediated protection. (Korean J Intern Med 2009;24:113-122)
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INTRODUCTION
Cilostazol, a quinolinone derivative synthesized by
Otsuka Pharmaceutical Co. (Tokushima, Japan), is a
specific inhibitor of phosphodiesterase III. Its principal
actions are associated with its ability to elevate intra-
cellular adenosine 3’,5’-cyclic monophosphate (cAMP)
levels, and include the inhibition of platelet aggregation
[1,2] and enhancement of the microcir-culation via
vasodilation [3]. The drug has been approved by the US
Food and Drug Administration for use in treating
intermittent claudication, which also involves its action in
inhibiting the breakdown of cellular cAMP [4].
Damage to large vessel and microvascular endothelium
is an important event in many forms of impaired organ
function under a variety of pathological tissue conditions,
including ischemia [5-7], shock [8], and sepsis [9].
Recently, several lines of evidence have suggested that
cilostazol provides beneficial effects in protecting cells
from injuries of diverse causes. Kim et al [10] reported a
protective effect of cilostazol against lipopolysaccharide
(LPS)-induced apoptosis in human umbilical veinendothelial cells (HUVECs). In their study, they demon-
strated a reversal by cilostazol of the LPS-induced decrease
in Bcl-2 and increases in Bax proteins and cytochrome c
release. Hong et al. [11] demonstrated the prevention of
tumor necrosis factor-alpha-induced cell death in human
neuroblastoma cells by cilostazol. An in vivo study in an
animal model of middle cerebral artery occlusion and
reperfusion also provided evidence for the protective
effect of cilostazol against cerebral infarcts evoked via
its anti-apoptotic actions. These reports provide consistent
evidence that cilostazol can reduce apoptotic cell death by
inhibiting the mitochondria-dependent apoptotic signaling
pathway [12]. However, the precise site and mechanism of
cilostazol-induced protection, apparently upstream of the
mitochondrial phase, remain unknown.
Members of the mitogen-activated protein kinase
(MAPK) family are important mediators of signal trans-
duction pathways that serve to coordinate the cellular
response to a variety of extracellular stimuli. Based on
structural differences, the MAPK family has been
classified into three major subfamilies: the extracellular
signal-regulated kinase (ERK1/2), the c-Jun N-terminal
kinase (JNK/SAPK), and the p38 MAPK [13] subfamilies.
These kinases are activated by phosphorylation of both
tyrosine and threonine residues catalyzed by specific
upstream MAPKs. Activated MAPKs phosphorylate their
specific substrates on serine and/or threonine residues,
ultimately leading to activation of various transcription
factors and control of a vast array of physiological processes,
including cell survival and death [14].
In this study, we examined the effects of cilostazol on
MAPK activity and its relationship with cilostazol-
mediated protection against apoptosis in LPS-treated
endothelial cells. HUVECs were exposed to LPS and
cilostazol with or without specific inhibitors of MAPKs,
and the changes in MAPK activity in association with
cell viability and apoptotic signaling were determined.
METHODS
Chemicals
The cilostazol was a gift from Dr. Rhim (Department
of Pharmacology, Pusan National University School of
Medicine, Korea). Lipopolysaccharides were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Ac-DEVD-
CHO, Z-IETD-FMC, Z-LEHD-FMK, Z-VAD-FMK, PD
98059, SB203580, SP600125, and U0126 were acquired
from Calbiochem (San Diego, CA, USA). TMRM,
calcein/AM and DiOC6(3) were obtained from Molecular
Probes (Eugene, OR, USA). Antibodies to cytochrome c,
Bcl-2, CREB, P-CREB, Bax, PERK1/2, P-p38, P-c-Jun and
α−actin were purchased from Cell Signaling Technology
(Beverly, MA, USA).
Cell culture
HUVECs, an endothelial cell line derived from the vein
of a normal human umbilical cord (CRL-2480; American
Type Culture Collection, Rockville, MD, USA), were
cultured in Ham’s F-12K medium supplemented with
10% heat-inactivated fetal bovine serum, 0.1 mg/mL
heparin sodium, 0.03-0.05 mg/mL endothelial cell
growth supplement, 100 U/mL penicillin, and 100 g/mL
streptomycin. Cells were grown to confluence at 37˚Ci n
a humidified 95% air/5% CO2 atmosphere in culture
dishes coated with 0.1% gelatin. When the cultures reached
confluence, subcultures were prepared, using a 0.02%
ethylenediaminetetraacetic acid (EDTA)/0.05% trypsin
solution.
Analysis of apoptosis
To detect apoptotic cells, the terminal transferase uridyl
nick end labeling (TUNEL) assay was performed using
the ApopTag Peroxidase In Situ Apoptosis Detection
Kit (Intergen, Purchase, NY, USA). Briefly, cells cultured
on coverglasses were exposed to experimental protocols
and fixed in 1% paraformaldehyde for 10 min. The fixed
cells were incubated with digoxigenin-conjugated dUTP
in a TdT-catalyzed reaction for 60 min at 37˚C and were
then immersed in stop/wash buffer for 10 min at room
temperature. The cells were then incubated with anti-
digoxigenin antibody conjugated with peroxidase for 30
min. The DNA fragments were stained using 3,3’-
diaminobenzidine (DAB) as a substrate.
Western blot analysis and immunoblotting
Cells were harvested and disrupted in lysis buffer
(1% Triton X-100, 1 mM ethylene glycol tetraacetic acid
(EGTA), 1 mM EDTA, 20 mM Tris-HCl (pH 7.4)). Cell
debris was removed by centrifugation (10,000 g, 10 min,
4˚C). The resulting supernatants were separated by 15%
SDS-PAGE under denaturing, reducing conditions and
transferred to nitrocellulose membranes. The membranes
were blocked with 5% nonfat dried milk at room tem-
perature for 30 min and incubated with antibodies against
phosphorylated ERK1/2 (P-ERK), and phosphorylated
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(PCREB), Bcl-2, and Bax. The membranes were washed
and incubated with the respective secondary antibodies.
The signals were visualized using an enhanced chemi-
luminescence system (Amersham, Buckinghamshire,UK).
Assay of JNK activity
JNK activity was assayed with a nonradioactive assay
kit, following the manufacturer’s protocol (Cell Signaling
Technology). Briefly, JNK protein was precipitated from
the cell lysate by a c-Jun fusion protein bound to
glutathione-Sepharose beads. C-Jun contains a high-
affinity binding site for JNK, particularly the NH2-
terminal region to the two phosphorylation sites, Ser-
63 and Ser73. After selectively pulling down JNK using
the c-Jun fusion protein beads, the beads were extensively
washed, and the kinase reaction was carried out in the
presence of cold ATP in a final volume of 20 µL. The
reaction was stopped with 25 µL of 2× Laemmli buffer and
loaded onto a 15% polyacrylamide gel. Protein was
transferred to nitrocellulose by electroblotting, and c-Jun
phosphorylation was selectively assessed using a
phospho-c-Jun antibody. This antibody specifically
measures JNK-induced phosphorylation of c-Jun at Ser-
63, a site important for c-Jun-dependent transcriptional
activity [15].
Determination of caspase activity
A quantitative enzymatic activity assay was carried out
using a colorimetric assay kit according to manufacturer’s
protocol (R&D Systems, Minneapolis, MN, USA). Cells
were harvested, washed with ice-cold phosphate-buffered
saline (PBS), lysed, centrifuged, and analyzed for total
protein by the Bradford assay. Reaction buffer (25 µL)
containing 10 mM dithiothreitol and 6 µL fluorogenic
caspase-specific substrate (DEVD-pNA for caspase 3,
Ac-IETD-pNA for caspase 8, and Ac-LEHD-pNA for
caspase 9) was added to each sample, and the samples
were incubated at 37˚C for 2 hour. Protease activity was
determined by measuring the relative fluorescence
intensity at 505 nm after excitation at 400 nm using a
luminescence spectrometer (LS50B; Perkin Elmer,
Buckinghamshire, UK). Results are shown as fold increases
in activity relative to untreated control cells.
Measurement of mitochondrial membrane 
potential
The mitochondrial transmembrane potential was
measured using DiOC6(3), a fluorochrome that is incorpo-
rated into cells depending on the mitochondrial membrane
potential [16]. Reduced DiOC6(3) staining indicates
disruption of the mitochondrial inner trans-membrane
potential. Cells were stained with DiOC6(3) at a final
concentration of 50nM for 20min at 37˚C in the dark.
Cells were washed and resuspended in PBS. The
fluorescence intensity was analyzed with a FACsort flow
cytometer (Becton Dickinson, Laguna Hills, CA, USA).
Confocal microscopic analysis of mitochondrial
permeability transition
To determine the changes in mitochondrial permeability
and membrane potential, a double-staining method with
fluorescent dyes, calcein-AM and tetramethylrhodamine
methyl ester (TMRM), was used as described by Lemasters
et al. [17] Intact mitochondria maintain an inside-negative
membrane potential and accumulate the lipophilic
cationic dye TMRM, with bright yellow fluorescence. As
calcein is impermeable to the inner mitochondrial
membrane, it does not enter the mitochondria. However,
mitochondrial dysfunction caused by a mechanism
referred to as the “mitochondrial permeability transition”
(MPT) makes the mitochondria permeable to solutes and
depolarizes the membrane potential. Thus, injured
mitochondria lose TMRM and become permeable to and
stained by calcein (green).
Statistical analyses
The data are expressed as means±SE. The significance
of difference between two groups was evaluated by
Student’s t-test. Multiple group comparisons were per-
formed using a one-way analysis of variance, followed by
the Tukey’s post hoc test. A p value <0.05 was deemed to
be statistically significant.
RESULTS
LPS-induced apoptosis and protection by
cilostazol
When HUVECs were assessed by TUNEL staining
after 18 hours exposure to 0.1 µg/mL LPS, apoptotic cells
with nuclear condensation and fragmentation were
observed (Fig. 1A). The extent of LPS-induced apoptosis
was concentration-dependent in the range from 0.01 to
1 µg/mL. At a concentration of 1 µg/mL, 47.6±6.8% of the
cells were counted as apoptotic (Fig. 1B). The results in
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cilostazol against LPS-induced apoptosis. The concen-
tration of cilostazol to reduce LPS-induced apoptosis by
50% was 1.1±24×10
-6 M. In the following experiments,
when cells were treated with cilostazol, a 10 µM concen-
tration was applied 15 min prior to exposure to LPS. At
this concentration, cilostazol provided protection against
LPS-induced apoptosis by 70.9±8.6%. Cilostazol alone
did not affect cell viability in the concentration range
tested (10
-7 to 10
-3 M).
LPS- and cilostazol-induced activation of MAPKs
To evaluate the possible involvement of MAPKs in the
LPS- and cilostazol-mediated changes in cell survival
signaling, activation of MAPK subfamilies was estimated
by measuring their phosphorylation levels. Cells were
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Figure 1. LPS-induced apoptosis and its protection by cilostazol. Cells were exposed to indicated concentrations of LPS in the presence or
absence of cilostazol for 18 hours. Cells were pre-treated with cilostazol 15 min prior to the exposure to LPS. Apoptotic cells were detected by
TUNEL assay. A. Representative micrographs of TUNEL-stained control and LPS-treated cells. Arrows indicate representative apoptotic cells.
B. Concentration-dependent effect of LPS to induce apoptosis. C. Concentration-dependent protection by cilostazol against apoptosis in LPS-
treated cells. Each point in B and C represents mean±S.E. of 4 experiments. *p<0.05 and **p<0.01 vs. respective controls without drugs (LPS
in B and cilostazol in C)
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Figure 2. LPS- and cilostazol-induced activation of MAPKs. Cells were treated with 1 µg/mL LPS (A) or 10 µM cilostazol (B) for the indicated
time periods, and the levels of phosphorylation for each MAPK subfamily were determined by Western blot analysis of cellular extracts.
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Figure 3. Effects of MAPK inhibitors on the LPS- and cilostazol-induced activation of MAPKs. Cells were treated with 1 µg/mL LPS (A) or 10
µM cilostazol (B) in the presence of different MAPK inhibitors (each 20 µM) for 45 min, and the phosphorylated levels of each MAPK subfamily
were determined by Western blot analysis of cellular extracts.
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Btreated with 1 µg/mL LPS or 10 µM cilostazol for the
indicated time periods. Cells treated with LPS exhibited
elevated phosphorylation levels of P-p38 and P-c-JUN.
Elevation of these phosphoprotein levels was apparent
after 15 min of treatment and reached peak levels at 30
min for P-p38 and 60 min for P-c-JUN. LPS caused no
significant change in the phosphorylation level of ERK1/2
(Fig. 2A). In contrast, cilostazol induced a marked
increase in ERK1/2 phosphorylation levels. Elevation of P-
ERK1/2 was detectable after 15 min of exposure to
cilostazol and reached a peak at 60 min. Cilostazol also
induced elevated phosphorylation levels in p38, although
it did not affect JNK activity (Fig. 2B). Elevation of these
phosphorylated proteins was selectively blocked by the
MEK1/2 inhibitor U0126 [18], the p38 MAPK inhibitor
SB203580 [19], and the JNK inhibitor SP600125 [20],
indicating that LPS- or cilostazol-induced changes in
these phosphorylated proteins was associated with
selective activation of MAPKs (Fig. 3).
Effects of MAPK inhibitors on apoptosis
To examine whether activation of the MAPK pathway
was involved in LPS-induced apoptosis and the protection
by cilostazol, the effects of MAPK inhibitors were studied.
In the absence of cilostazol, LPS-induced apoptosis was
unaffected by U0126 or SB20350, suggesting that LPS
evoked apoptosis through a mechanism independent of
ERK1/2 or p38 MAPK. In contrast, U0126 significantly
reduced the cilostazol-mediated protection against
apoptosis in LPS-treated cells. SB203580 also reduced
cilostazol-mediated protection (Fig. 4). These results,
consistent with those in Figures 2 and 3, suggest that the
signaling mechanism underlying the cilostazol-mediated
protection against apoptosis in LPS-treated cells was
associated with activation of the ERK1/2 and p38 MAPK
pathways.
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Figure 4. Effects of MAPK inhibitors on LPS-induced apoptosis
and protection from it by cilostazol. Cells were treated with 1 µg/mL
LPS or 10 µM cilostazol in the presence of different MAPK inhibitors
(each 20 µM) for 18 hours. Apoptotic cells were detected by the
TUNEL assay. Each bar represents the mean±SE of five experiments.
* p<0.01 vs. control.
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Figure 5. Effects of LPS on caspase activity. Cells were treated
with 1 µg/mL LPS for the indicated time periods and assayed for
caspases 3, 8, and 9 activity. Each bar represents the mean±SE of
five experiments. * p<0.01 vs. respective control.
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Figure 6. Effects of caspase inhibitors on LPS-induced apoptosis.
Cells were treated with 1 µg/mL LPS in the presence of different
caspase inhibitors (each 20 µM) for 18 hours. Apoptotic cells were
detected by the TUNEL assay. The number of apoptotic cells is
represented as the percentile of total cell counts. Each bar represents
the mean±SE of six experiments. * p<0.05, † p<0.01 vs. control.
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Activation of caspase cascades is key for the execution
phase of apoptosis. Caspase 9 is activated by cytochrome
c released from mitochondria and is thus crucial for the
execution of mitochondria-dependent apoptosis, whereas
caspase 8 is activated largely through a mitochondria-
independent mechanism [17]. Caspase 3, which is activated
by the active form of caspase 8 or 9, is a protease that
mediates apoptosis. To delineate the role of these caspases
in the LPS-induced apoptosis, we investigated the activa-
tion pattern of these caspases in LPS-treated cells. Cells
were treated with 1 µg/mL LPS for the indicated time
periods and the lysate was incubated with a fluorogenic
substrate, the Ac-LEHD-fmk motif, of the enzyme. LPS-
induced activation of caspase 9 showed a time-dependent
and sustained pattern. The activity reached a peak (3.1-
fold increase) at 3 hour and remained elevated up to 18
hours. In contrast, caspase 8 was transiently activated by
LPS, showing peak activity (1.9-fold increase) at 30 min,
followed by a return to the control value at 3 hour. Acti-
vation of caspase 3 was similar to that of caspase 9 (Fig. 5).
To delineate the role of these caspases in LPS-induced
apoptosis, the effects of caspase inhibitors were examined.
Z-LEHD-FMK [21] and Ac-DEVD-CHO [22], specific
inhibitors of caspases 9 and 3, respectively, and the
broad-range caspase inhibitor, Z-VAD-FMK [23], all
markedly prevented LPS-induced apoptosis. In contrast,
the caspase 8 inhibitor Z-IETD-FMK [24] showed only
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Figure 7. Effects of MAPK inhibitors on LPS- and cilostazol-
induced changes in caspase activity. Cells were treated with 1 µg/mL
LPS with and without 10 µM cilostazol in the presence of different
MAPK inhibitors (each 20 µM) for 45 min, and assayed for caspases
3, 8, and 9 activities. Each bar represents the mean±SE of four
experiments. * p<0.01 vs. control.
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Figure 8. Effects of LPS, cilostazol, and MAPK
inhibitors on the mitochondrial membrane potential.
Cells were treated with 1 µg/mL LPS with and without 10
µM cilostazol, in the presence of different MAPK
inhibitors (each 20 µM) for 6 hour and loaded with
DiOC6(3). Mitochondrial membrane potential was
evaluated by flow cyto-metric analysis of DiOC6(3)
fluorescence.
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M2a minimal protective effect (Fig. 6). These results suggest
that activation of caspase 9 through a mitochondria-
dependent mechanism plays a key role in LPS-induced
apoptosis in HUVECs.
Effects of MAPK inhibitors on caspase activity
To delineate the link between cilostazol-mediated
activation of MAPKs and the inhibition of caspase
activation, the effects of U0126 and SB203580 on caspase
activity in LPS- and/or cilostazol-treated cells were
examined. LPS transiently activated caspase 8 (Fig. 5).
It was unaffected by U0126 and SB203580 in the presence
or absence of cilostazol. In contrast, LPS-induced acti-
vation of caspases 9 and 3 were markedly inhibited by
cilostazol. Moreover, U0126 and SB203580 effectively
blocked the cilostazol-mediated inhibition of this caspase
activation (Fig. 7). These results suggest that cilostazol
protected HUVECs against LPS-induced apoptosis
through inhibiting caspase 9 and 3 activity, and that this
was associated with stimulation of ERK 1/2 and p38
MAPK signaling.
Effects on LPS-induced changes in mitochondrial
integrity
The results described thus far suggest that activation
of the caspase cascade through a mitochondria-dependent
mechanism plays a key role in LPS-induced apoptosis
and cilostazol-mediated protection. In the next series of
experiments, changes in mitochondrial integrity in cells
treated with LPS with and without cilostazol and the effects
of MAPK inhibitors were examined. Figure 8 shows flow
cytometric analyses of DiOC6(3)-stained cells. In the
graphs, the left shift of DiOC6(3) fluorescence signals
indicates depolarization of the mitochondrial membrane
potential. LPS significantly depolarized the mitochondrial
membrane potential and cilostazol effectively reversed
this effect. In the presence of U0126 and SB203580,
cilostazol-mediated prevention of mitochondrial depo-
larization in LPS-treated cells was abolished (Fig. 8).
Consistent with this, cilostazol significantly reduced
the LPS-induced release of cytochrome c into the cytosol.
U0126 and SB203580 also interfered with the action of
cilostazol in this process (Fig. 9).
Effects on LPS-induced mitochondrial
permeability transition
In the process of mitochondria-dependent apoptosis,
disruption of the permeability barrier of the inner mito-
chondrial membrane (i.e., MPT) precedes the release of
cytochrome c through the MPT pore [25]. We sought to
visualize the LPS-induced MPT by confocal microscopy
of cells that were double-stained with the fluorescent
dyes TMRM and calcein-AM. Intact mitochondria with
a negative membrane potential accumulate the lipophilic
cationic dye TMRM. As a result, mitochondrial contours
are visualized as bright red spots (left upper and left
lower micrographs in Fig. 10A). In cells doubled-stained
with TMRM and mitotracker green (MTG), it is evident
that these dyes accumulate at the same loci, as shown in
the merged micrograph in the right upper panel of Figure
10A. Calcein, in an acetoxymethylester form (calcein-AM),
readily penetrates the cell membrane. In the cytoplasm,
esterases hydrolyze calcein-AM into the free acid form.
As it is impermeable to the inner mitochondrial mem-
brane, calcein does not enter intact mitochondria, and it
resides in the cytoplasm and nuclei (middle and right
micrographs in the lower panel of Fig. 10A). 
However, injured mitochondria in cells exposed to LPS
tend to lose TMRM and become permeable to calcein. As
a result, it becomes hard to distinguish the mitochondrial
contours from the cytosol in micrographs (e.g., the left
micrographs in Fig. 10B). These results show evidence
of MPT in LPS-treated cells. In this event, as well as mito-
chondrial depolarization and cytochrome c release, as
shown in the previous results, cilostazol prevented or
delayed LPS-induced MPT, and MEK1/2 inhibitors
interfered with this action of cilostazol.
Effects on CREB phosphorylation and Bcl-2 and
Bax expression
Phosphorylation of CREB is required for its tran-
scriptional activation [26]. Although PKA is an important
kinase for CREB phosphorylation, it has been reported
that phosphorylation can occur independently of PKA,
through ERK1/2 and p38 MAPK [27]. Thus, we hypothe-
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Figure 9. Effects of LPS, cilostazol, and MAPK inhibitors on the
cytosolic release of cytochrome c. Cells were treated with 1 µg/mL
LPS with and without 10 µM cilostazol, in the presence of different
MAPK inhibitors (each 20 µM) for 18 hours, and Western blot
analysis was performed for cytochrome c in the mitochondrial and
cytosolic fractions of cell extracts.
mitochondria
LPS
CSZ
U0126
SB203580
-+ +++
-- ++ +
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-- --+sized that cilostazol may stimulate CREB phosphorylation
through ERK1/2- and p38 MAPK-dependent pathways.
As shown in Figure 11A, MEK1/2 and p38 MAPK inhibitors
significantly suppressed the cilostazol-stimulated
phosphorylation of CREB. Apoptotic death signals
converge on the mitochondria through the activation of
pro-apoptotic members of the Bcl-2 family, such as Bax,
while Bcl-2 serves as an anti-apoptotic protein [28]. As
demonstrated in Figure 11B, cilostazol stimulated Bcl-2,
while it suppressed LPS-induced Bax expression. These
effects of cilostazol were antagonized by MEK1/2 and
p38 MAPK inhibitors.
DISCUSSION
The major findings of the present study are that
cilostazol protected HUVECs against LPS-induced
apoptosis by suppressing the mitochondrial permeability
transition, the cytosolic release of cytochrome c, and the
subsequent activation of caspases. Moreover, it stimulated
ERK1/2 and p38 MAPK signaling and increased phospho-
rylated CREB and Bcl-2 expression, while suppressing
Bax expression. In addition, these cilostazol-mediated
cellular events could be effectively blocked by MEK1/2
and p38 MAPK inhibitors. The effect of cilostazol in
inhibiting LPS-induced apoptosis has been reported
previously [10-12]. The present study adds new aspects
to the signal transduction pathway of this cilostazol-
mediated protection and emphasizes the involvement of
the ERK1/2 and p38 MAPK signaling pathways. 
LPS, a complex glycoprotein that resides in the outer
membranes of Gram-negative bacteria, has been impli-
cated as a causative agent in endothelial injury, a pivotal
event that can lead to septic shock and associated syn-
dromes [29]. Previous studies have shown that LPS
induces apoptosis in different types of endothelium,
including HUVECs [30,31] and lung-derived [32] normal
human microvascular endothelial cells. It has also been
reported that the release of LPS into the circulation induces
endothelial apoptosis in vivo and thus causes microvas-
cular injury in numerous tissues, including the lung, gut,
and liver, during sepsis [29,33]. Tissues and organs
obtained from patients who have died of sepsis and multi-
organ failure [29] and animal models of endotoxemia and
sepsis reveal enhanced apoptotic cell death [34,35].
Although apoptosis has been implicated as an impor-
tant mechanism of in vivo cell death following LPS expo-
sure, the molecular pathways of apoptosis in endothelial
cells are still controversial. Bannerman et al. [30] suggested
that LPS-induced apoptosis in HUVECs was mediated
through activation of caspase 8 via interaction with Toll-
120 The Korean Journal of Internal Medicine Vol. 24, No. 2, June 2009
Figure 10. Induction of mitochondrial permeability transition
and protection against it by cilostazol, as visualized by confocal
micro-scopy. (A) Control cells were double-stained with
TMRM/MTG or TMRM/calcein. (B) Cells were treated with 1
µg/mL LPS with and without 10 µM cilostazol in the presence or
absence of U0126 (20 µM) for 6 hours and were double-stained with
TMRM and calcein-AM.
TMRM MTG TMRM / MTG LPS LPS+CSZ LPS+CSZ+U0126
TMRM Calcein TMRM / Calcein
A B
Figure 11. Effects of LPS, cilostazol, and MAPK inhibitors on (A)
pho-sphorylation of CREB, and (B) expression of Bcl-2 and Bax
proteins. Cells were treated with 1 µg/mL LPS with and without 10 µM
cilostazol in the presence of different MAPK inhibitors (each 20 µM)
for 6 hours, and Western blot analysis was performed for
phosphorylated CREB, Bcl-2, and Bax proteins in the cell extracts.
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-+- - - + + +
--++ ++ + +
---+ - - + -
---- +- - +like receptor (TLR)-4, which is expressed on the endothe-
lial cell membrane. However, Munshi et al. [31] reported
that LPS did not exert any significant effect on caspase 8
activity in these cells, and that LPS-induced apoptosis was
mediated independently of caspase 8 activation. In the
present study, activation of caspase 9 was more prominent
than that of caspase 8. Moreover, the caspase 8 inhibitor
Z-IETD-FMK was much less effective than the caspase 9
or 3 inhibitors in suppressing LPS-induced apoptosis.
This study also demonstrated that deterioration of mito-
chondrial integrity preceded the execution of apoptosis in
LPS-treated cells. These results suggest that the sequential
activation of caspases 9 and 3, through a mitochondria-
dependent pathway, is a crucial intracellular signaling
event in the LPS-induced apoptosis of HUVECs.
MAPKs regulate cellular activities ranging from gene
expression, mitosis, motility, and metabolism to apoptosis.
It is generally believed that ERKs are important for cell
survival, while JNKs and p38 MAPKs have been deemed
stress-responsive, and thus involved in apoptosis. However,
the regulation of apoptosis by MAPKs is more complex
than once thought and remains controversial. The
ERK1/2 pathway is primarily induced in response to
mitogens and growth factors and plays a major role in
regulating cell growth, survival, and differentiation
[36,37]. In contrast, the JNK and p38 pathways are
activated in response to chemical and environmental
stresses. Their activation is frequently associated with
the induction of apoptosis [15,37].
The present study suggests that the activation of
ERK1/2 and p38 MAPK plays an important role in the
cilostazol-mediated inhibition of LPS-induced apoptosis.
The drug induced sustained elevation of phosphorylated
ERK1/2 and p38. Moreover, the ERK1/2 upstream
kinase MEK1/2 inhibitor U0126 [18] and the p38 MAPK
inhibitor 203580 markedly suppressed the cilostazol-
mediated inhibition of LPS-induced apoptosis and
activation of caspases 9 and 3. The effects of the MAPK
inhibitors on the mitochondrial events associated with
cilostazol-mediated protection were consistent with the
belief that these MAPKs play pivotal roles in the cellular
signaling events for the cilostazol-mediated anti-apoptotic
effect. Furthermore, confocal microscopy provided
direct evidence for a role of these MAPKs in the cilostazol-
mediated prevention of the mitochondrial permeability
transition, a key event for the initiation of mitochondria-
dependent apoptotic signaling.
It is generally accepted that cAMP-mediated trans-
criptional responses involve the ability of PKA to pho-
sphorylate CREB [26]. However, an alternative mecha-
nism has been proposed whereby cAMP promotes
phosphorylation of CREB through ERK1/2 and p38
MAPK, and perhaps other protein kinases too. In the
present study, cilostazol-stimulated phosphorylation
of CREB was significantly reduced by MEK1/2 and
p38 MAPK inhibitors, indicating the involvement of
these MAPKs in the signaling of CREB phosphorylation.
The cyclic AMP response element is a major positive
regulatory site in the Bcl-2 promoter [38]. Thus, the
increased expression of Bcl-2 by cilostazol and its
inhibition by MAPK inhibitors in this study seem to
reflect the consequences of CREB phosphorylation.
In conclusion, the present study demonstrated that
cilostazol protected HUVECs against LPS-induced
apoptosis by suppressing mitochondria-dependent
apoptotic signaling. Activation of ERK1/2 and p38
MAPKs, and subsequent stimulation of CREB phospho-
rylation and Bcl-2 expression, may be responsible for the
cellular signaling mechanism of cilostazol-mediated
protection.
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